These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36562554)

  • 21. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
    Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
    J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective review.
    Guenther EL; McCoy KS; Eisner M; Bai S; Nemastil CJ; Novak KJ; Johnson T; Stephan EM
    J Cyst Fibros; 2024 Jan; 23(1):32-37. PubMed ID: 37069044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
    N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
    Borgo C; D'Amore C; Capurro V; Tomati V; Sondo E; Cresta F; Castellani C; Pedemonte N; Salvi M
    Cell Mol Life Sci; 2022 Mar; 79(4):192. PubMed ID: 35292885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.
    Sakon C; Vogt H; Brown CD; Tillman EM
    Pediatr Pulmonol; 2023 Mar; 58(3):662-664. PubMed ID: 36482831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.
    Zaher A; ElSaygh J; Elsori D; ElSaygh H; Sanni A
    Cureus; 2021 Jul; 13(7):e16144. PubMed ID: 34268058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
    Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
    J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
    Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
    Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor.
    Baroud E; Chaudhary N; Georgiopoulos AM
    Pediatr Pulmonol; 2023 Jul; 58(7):1920-1930. PubMed ID: 37036050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
    Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
    Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
    Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.
    Caley LR; Jarosz-Griffiths HH; Smith L; Gale L; Barrett J; Kinsey L; Davey V; Nash M; Jones AM; Whitehouse JL; Shimmin D; Floto RA; White H; Peckham DG
    J Cyst Fibros; 2023 Nov; 22(6):1002-1009. PubMed ID: 37422432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis.
    Gabillard-Lefort C; Casey M; Glasgow AMA; Boland F; Kerr O; Marron E; Lyons AM; Gunaratnam C; McElvaney NG; Reeves EP
    Am J Respir Crit Care Med; 2022 Apr; 205(7):783-794. PubMed ID: 35021019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.